






Curative Immunology Through Myeloid Reprogramming

MISSION

Our Mission is **Personal**

My Aunt passed away due to Rheumatoid Arthritis-related complications and,
My Youngest Sister struggling with ulcerative colitis for 15 years cycling through therapies



THE PROBLEM

Numbers too big to ignore

1 in 10 People in the world have an Autoimmune Disease.


80% of Autoimmune Disease patients are **Females**.

Autoimmune Diseases are **Rapidly** Rising, **+19%** annually.

40-60% non-response to today's best drugs.

TRADITIONAL THERAPIES

Leave a lot unsolved



→ Approved drugs aren't durable, durable approaches aren't scalable.

CELLS AND STRATEGY


Targeting the master regulators

Our Target: Myeloid cells

- On-site **guardians** and **orchestrators** of the immune response.
- Can **acquire trained immunity**.


Our Strategy: *in vivo* reprogramming

- **Retrain** the immune orchestra **locally** by flipping the conductors (myeloid master regulators) to a healthy transcriptional state



THE ARES PLATFORM

The Engine Behind Cell-State Healing




OUR DATASET

OUR PLATFORM

OUR PRODUCT

WE START HERE

Targeting Myeloid Master Regulators in Rheumatoid Arthritis



We are building the best biology-faithful in vitro
and ex vivo model of disease states

We are building the world's most comprehensive data atlas
of cell states in rheumatoid arthritis.

We discover healing drugs

PLATFORM BUILDER, BUILDING AGAIN

Proven serial drug discovery platform builder



Rihab Gam, PhD | Founder

Head of Biology at Elastin Biosciences (**1st hire**)

Head of Target Validation at Shift Bioscience (**1st Senior hire**)

Built Cell Reprogramming Platforms, MRC-LMB in Cambridge (as Rutherford Postdoctoral Fellow) and at **Shift Bioscience/Elastin Bioscience**.





MRC Laboratory
of Molecular Biology



UNIVERSITY OF
CAMBRIDGE



Pitch Competition Finalist



Company Seeding Fellow

ADVISORS

Successful Science-First Entrepreneurs



Prof. Julian Gough, PhD

4x Biotech Founder

Founder & CEO at **Outsee** (raised \$3M)

Founder and Director at **Mogrify** (raised \$50M).

Past: Programme Leader and Professor,
MRC-LMB, Cambridge



Prof. Junyue Cao, PhD

Genomics Tech Expert


Head of Laboratory, **Rockefeller**

Past: Developed foundational single-cell
genomics tech commercialized by **Scale**

Biosciences (raised \$32M, acquired by 10X)

THE COMPETITIVE LANDSCAPE

A Unique And Defensible Position



- **Closing the gap:** Targeting the **40–60%** of patients left behind by today's best drugs.
- **De-risked entry:** Starting in **the joint, local, measurable** and **safe**.
- **Proven biology:** **Myeloid cells** were reprogrammed in vivo in **cancer**. We're harnessing that.
- **Small molecules:** **repeatable, scalable, and expandable** across autoimmune diseases.
- **ARES Potential:** Predict **drug combinations, toxicity** and **off-targets**.

THE MARKET

A Multi-Billion Dollar Market Ripe for Disruption

Benchmark Exits Show the Scale of The Opportunity

Amgen → Horizon

Tepezza for TED/Graves', **\$27.8B**, 2023.

Merck → Prometheus Biosciences

Autoimmune, Antibody, **\$10.8B**, 2023.

Roche → Telavant


TL1A for IBD **\$7.1B**, 2023.

Lilly → Dice

Oral IL-17 for dermatitis/rheum, **\$2.4B**, 2023.


Takeda → Nimbus

Oral TYK2 for IBD, arthritis, SLE, **\$4B**, 2023.



THE ROADMAP

Our Milestones





Reprogramming Immunity. Restoring Health.

Our Core Belief

“Patients deserve more than a lifetime of symptom management.”